Among the three biotech stocks to watch going forward in 2021 highlighted by the author of today’s article is a specialty company focused on developing… Read More »3 Biotech Stocks To Watch – Including A Pioneering CBD Company
The genomic revolution in underway, with the author of today’s article noting that “artificial intelligence is converging with decades of breakthrough genomics research to create a new generation of hyper-efficient, hyper-accurate, and hyper-precise gene editing medicines.”
“Investors who want the massive potential gains from penny stock investing should focus on those with a real business producing real cash,” advise the authors… Read More »“Real Businesses Producing Real Cash”: 3 Penny Stocks Poised To Benefit From Major Market Trends
Four biotech penny stocks with upside to analyst price targets ranging from 42% to 291%.
or these five stocks – which include a smaller cap mining company and a small-cap biotech play focused on developing specialty products for underserved patient populations read more!
The author of today’s article notes that high-profile IPOs typically follow a pattern – and given this pattern, he is bullish on “a biotech stock that went public just under a month ago with a story that perfectly fits the times, and whose stock has followed exactly that pattern.”
Small- And Mid-Cap Biotech Picks For 2021 and holdovers from 2020.
When it comes to biotech investing in 2021, healthcare stock analysts at RBC advised in a recent report that “Many pandemic-related influences are setting up the sector for outperformance but several factors could still work against the group, making individual stock selection a key priority…”
One-size-fits-all drugs are giving way to precision medicine, which the author of today’s article expects will come to dominate the health care marketplace in the next three to five years.
The small-cap biotech featured in today’s article has been on a wild trading ride in recent days, having surged 1,600% in two days on enthusiasm for its immunotherapy treatment for breast cancer, clinical trial results for which demonstrate 0% recurrence of the disease at a median of five years in patients who received the treatment following surgery and Herceptin treatment.